GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (LTS:0A5V) » Definitions » Short Percentage of Float

Viatris (LTS:0A5V) Short Percentage of Float


View and export this data going back to 2015. Start your Free Trial

What is Viatris Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Viatris's Short Percentage of Float

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viatris's Short Percentage of Float Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Viatris's Short Percentage of Float falls into.


Viatris (LTS:0A5V) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (LTS:0A5V) » Definitions » Short Percentage of Float
Comparable Companies
NBIX CTLT ITCI ELAN LNTH PRGO ALKS ALVO PBH AMPH ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ SZSE:000538 HKSE:03692 TSE:4507
Traded in Other Exchanges
VTRS:USA MYL:Mexico 1VTRS:Italy VIA:Germany MYL:Austria
Address
1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Website
https://www.viatris.com
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris (LTS:0A5V) Headlines

No Headlines